Nonthrombocytopenic purpura developed in a patient receiving hexamethylene bisacetamide, a tumor-differentiating agent in vitro that is in phase I clinical trials. Histopathological examination revealed features of leukocytoclastic vasculitis with deposition of IgA and complement in the dermal vasculature. Leukocytoclastic vasculitis, an extremely rare complication of therapy with antineoplastic agents, is reported to alert others using this compound of this association.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cancer Treatment Reports|
|State||Published - Sep 15 1987|
ASJC Scopus subject areas
- Cancer Research